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ABSTRACT
Here we report a case of primary epithelioid angiosar-
coma (e a s ) of the breast occurring in a 30-year-old 
woman. Following fine-needle asspiration cytology 
(f n a c ) and tru-cut biopsy, the patient was initially 
diagnosed with mammary carcinoma and thereafter 
underwent modified radical mastectomy. Postop-
erative histopathologic examination and immunohis-
tochemistry revealed a diagnosis of primary epithe-
lioid angiosarcoma of the breast. The patient received 
postoperative radiotherapy to the chest wall and was 
started on adjuvant thalidomide. Preoperatively, e a s  
can be mistaken for carcinoma because it is difficult to 
appreciate the typical morphology on f n a c  or tru-cut 
biopsy. Indeed, this is an area of potential diagnostic 
error because, nowadays, neoadjuvant therapy is often 
instituted after core biopsy of a breast mass. This case 
is being reported not only for its diagnostic difficulty, 
but also because of its rarity in English literature.
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1.  INTRODUCTION
Sarcomas represent fewer than 1% of primary breast 
malignancies 1,2. The most commonly reported 
primary non-phyllodes sarcomas of the breast are 
angiosarcoma, fibrosarcoma, malignant fibrous 
histiocytoma, liposarcoma, and leiomyosarcoma 2. 
Angiosarcomas account for fewer than 0.05% of all 
malignant mammary tumours 3.
Angiosarcomas of the breast are commonly seen 
secondary to radiation therapy; they are also associ-
ated with postoperative lymphedema (Stewart–Treves 
syndrome). In comparison, primary angiosarcomas are 
relatively rarer. Secondary angiosarcomas arise from 
skin and show a pattern of infiltration into breast from 
skin and subcutaneous tissues. In contrast, primary 
angiosarcomas arise from mammary tissues and 
infiltrate the skin only in advanced cases. The grading 
of the tumour is thought to affect prognosis more in 
primary angiosarcomas; it has questionable value in 
prognosticating secondary angiosarcomas 4.
Primary epithelioid angiosarcoma (e a s ) is distinc-
tively rare in the breast and was first reported by Weiss 
and Enzinger in 1982 5. It has been more frequently 
reported in other sites such as the skin 6, uterus 7, 
small intestine 8, lung 9, thyroid 10, and central nervous 
system and orbit 11. About 100 cases of secondary 
angiosarcoma of the breast after breast-conserving 
therapy have been reported, but primary e a s  of the 
breast is rare 12. After an extensive literature search 
using key words such as “e a s ,” “breast,” and “pri-
mary” in PubMed, Scopus, Ovid, and IngentaCon-
nect, we could identify only 9 cases of primary e a s  
of the breast 13–16.
The striking preoperative difficulty in diagnos-
ing these lesions may be attributable to a limitation 
in cells or tissue yielded by fine-needle aspiration 
cytology (f n a c ) and tru-cut biopsy. A misdiagnosis of 
carcinoma may lead to delay in initiating the aggres-
sive management needed, given that angiosarcomas 
are the most malignant of all breast tumours 17.
We were recently confronted with a case of 
nonmetastatic primary e a s  of the breast that was 
diagnosed preoperatively as infiltrating ductal carci-
noma. Here we discuss the clinical, pathologic, and 
immunohistochemical features of the case with an 
intent to convey the diagnostic dilemmas involved.
2.  CASE DESCRIPTION
A 30-year-old premenopausal woman presented to a 
peripheral hospital with a 15-day history of a painless 
lump in the right breast in which f n a c  was suggestive 
of carcinoma. This patient was then referred to the 
breast cancer clinic at our institute. On physical ex-
amination, a lump measuring 6×5 cm was detectable 
centrally in the right breast. This lump was hard in 
consistency and not fixed to the underlying structure. 
Overlying skin was unremarkable. No axillary or 
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supraclavicular lymph nodes were palpable. The 
contralateral breast and axilla were normal.
As initial screening, a f n a c  was advised, followed 
by tru-cut biopsy of the lump. A diagnosis of high-grade 
carcinoma was suggested in both tests. Immunohis-
tochemical staining for cytokeratin was positive in tu-
mour cells; staining for vimentin was negative. The cells 
were negative for the estrogen and progesterone receptor 
immunostains, but 2+ positivity for the human epidermal 
growth factor receptor [h e r 2/neu (ErbB2)] was noted. 
Chest radiography, abdominal ultrasonography, and bone 
scan did not reveal any metastatic disease.
Based on the overall preoperative workup, a 
diagnosis of carcinoma of the right breast T3N0M0 
was made. A preoperative mammogram was not done, 
because right modified radical mastectomy (m r m ) 
followed by adjuvant therapy was planned for the 
patient and performed in July 2008. Intraoperatively, 
the lump was close to deep fascia; a cuff of pectoralis 
major muscle was therefore excised along with tu-
mour. The axillary dissection proceeded to the level 3 
lymph node, because multiple lymph nodes, the larg-
est being 1.5 cm, were present at levels 1 and 2.
2.1  Pathology Findings
2.1.1  FNAC
On aspiration of the lesion, cellular yield was moderate, 
comprising predominantly single cells with occasional 
cell clusters. The tumour cells were noted in a back-
ground of blood, together with scattered histiocytes 
and neutrophils. The tumour cells were epithelioid 
with eccentric nuclei, coarse chromatin. and moderate-
to-abundant cytoplasm with an indistinct margin. The 
nuclear margin was irregular with identifiable nuclear 
indentation. Fine cytoplasmic vacuolations were identi-
fied. Based on morphology, a possibility of high-grade 
malignancy was considered [Figure 1(a,b)].
f i g u r e  1  (a,b) Fine-needle aspiration cytology of the breast lesion showed singly-lying epithelioid cells with irregular pleomorphic nuclei 
and moderate-to-abundant bluish cytoplasm [Giemsa stain: (a) 200×, (b) 400×]. (c,d) Tru-cut biopsy of the breast showed irregular cords and 
singly-lying pleomorphic cells with moderate cytoplasm and focal necrosis [hematoxylin and eosin stain: (c) 40×, (d) 100×]. (d, inset) The 
cells were immunopositive for cytokeratin (40×).66
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2.1.2  Tru-Cut Biopsy
Based on a suggestion from the f n a c  report, a tru-cut 
biopsy was planned. The biopsy comprised one core 
showing high-grade malignancy with epithelioid 
cell morphology. The cells were raggedly infiltrating 
the fibrocollagenous stroma. Focal hemorrhage was 
noted, but no definite identifiable vascular lumen was 
seen. The cells had moderate eosinophilic cytoplasm. 
Few mitotic figures and areas of focal necrosis were 
seen. No definite ductal pattern or residual benign 
ducts were noted in this biopsy [Figure 1(c,d)]. An 
immunohistochemical panel including cytokeratin 
(c k ); vimentin; estrogen (e r), progesterone (p r), and 
h e r 2/neu receptor proteins; and thyroid transcrip-
tion factor was applied. Among these, c k  and h e r 2/
neu were positive in tumour cells, and a diagnosis of 
primary breast carcinoma was given.
2.1.3  MRM Specimen
The gross resected m r m  specimen measured 
10×11×6 cm. On sectioning, a spongy hemorrhagic 
tumour measuring 7×6×2.8 cm was seen centrally and 
in the upper outer quadrant. The tumour was close to 
the pectoralis fascia.
Multiple sections showed features of a poorly dif-
ferentiated malignant tumour with entrapped benign 
ductules at the tumour periphery [Figure 2(a)]. The 
tumour was composed of pleomorphic epithelioid 
cells, multinucleated giant cells, slit-like vascular 
spaces, fresh and old hemorrhage, necrosis, and 
scattered inflammatory cells [Figure 2(b)]. The epi-
thelioid cells showed indented hyperchromatic nuclei 
and a moderate amount of eosinophilic cytoplasm 
[Figure 2(c)]. Mitotic activity was identified. These 
cells were seen lining the vascular spaces.
f i g u r e  2  (a) Low-power photomicrograph of the resected tissue shows an infiltrating malignant tumour entrapping the residual ductules 
(hematoxylin and eosin stain, 40×). (b) The tumour is highly vascular, comprising many large and slit-like vascular spaces (hematoxylin and 
eosin stain, 200×). (c) The slit-like spaces are lined by pleomorphic epithelioid malignant cells. Few giant cells are noted (hematoxylin and 
eosin stain, 400×). (d) The tumour cells are strongly immunopositive for CD31 (200×). (d, inset) Immunostaining for the human epidermal 
growth factor receptor (h e r 2/neu) was positive in tumour cells (200×).67
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The tumour cells were immunopositive for CD31, 
and 2+ immunopositivity for h e r 2/neu was noted 
[Figure 2(d)]. The cells were negative for CD34 and 
the e r and p r immunostains.
Overall features of the tumour were compat-
ible with an e a s  of the breast. The overlying skin, 
nipple, areola, and deep resected margins were free 
of tumour. All 13 lymph nodes dissected were free 
of tumour.
Postoperative computed tomography imaging 
of the chest (for ruling out lung metastasis) was 
normal. Left mammogram showed a normal study. 
The patient was planned for adjuvant radiotherapy 
and chemotherapy. She received chest wall telecobalt 
radiotherapy, 50 Gy in 25 fractions over 5 weeks, us-
ing two tangential fields. She tolerated radiotherapy 
well, with grade 1 skin reactions.
Because the role of chemotherapy is not well 
defined in this disease, the patient was started on 
thalidomide 100 mg daily based on previous experi-
ence at our institute 18. She developed asymptomatic 
rashes over her thighs, which resolved spontaneously. 
She is clinically disease free at 11 months after sur-
gery. This patient has been receiving thalidomide for 
10 months and is tolerating it well. We are planning 
to continue thalidomide till disease recurrence or 
intolerance to thalidomide.
3.  DISCUSSION
Epithelioid angiosarcoma is a rare variant of angiosar-
coma described in various sites. Only 4 individual 
cases of primary e a s  of breast have been described 
previously 13–16, and 5 cases were mentioned in a clini-
copathologic series reported by Nascimento et al. 3 
of 49 cases of primary angiosarcoma of breast. The 
tumour is most common during the third and fourth 
decades of life. It may present as a small painless lump 
or even as a large hemorrhagic mass. In advanced 
cases, there may be skin involvement, ulceration, and 
bleeding. Table i enumerates the clinical, pathologic, 
and immunohistochemical features and management 
of the cases that have been described in detail in the 
English literature (excluding the cases mentioned by 
Nascimento et al.).
Epithelioid angiosarcoma is composed predomi-
nantly or exclusively of large, rounded “epithelioid” 
endothelial cells with abundant amphophilic or 
eosinophilic cytoplasm and large vesicular nuclei. 
Initial preoperative incisional biopsy can lead to a 
misdiagnosis of ductal carcinoma because of similar 
histopathology. Both diseases can show solid sheets 
of polygonal cells with intracytoplasmic clear spaces 
or vacuoles. Only primary e a s  shows slit-like vascular 
spaces, which are lined with pleomorphic epithelioid 
malignant cells. The differential diagnosis of primary 
e a s  of the breast includes ductal carcinoma and other 
poorly differentiated sarcomas 19.
In our case, the diagnosis was missed on the f n a c  
and tru-cut biopsies, and e a s  of breast is known to be 
able to mimic a high-grade carcinoma in a f n a c  smear 
or tru-cut biopsy core. Although the cells in our case 
had nuclear indentation, the absence of cytoplasmic 
vacuolations, vesicular nuclei, and identifiable vas-
cular channels in the tru-cut biopsy core led us away 
from the correct diagnosis 20,21.
t a b l e  i  Cases of primary epithelioid angiosarcoma of the breasta
Reference Patient Treatment Immunohistochemistry Outcome
Age Sex [positive (+), negative (–)]
(years)
Martinez et al., 1997 13 26 F Modified radical mastectomy,
postoperative radiotherapy 
(4860 cGy), doxorubicin  
and dacarbazine
Vimentin+, factor viii+,
CD31+, cytokeratin–
Alive at 7 months,
with local recurrence
Farina et al., 2003 14 49 F Modified radical mastectomy,
no adjuvant
Vimentin+, factor viii+,
CD31+, CD34+, cytokeratin–
Died at 15 months
of metastasis
Carter et al., 2005 15 33 F Simple mastectomy, no adjuvant n r Alive at 7 months,
with axillary recurrence
Wang et al., 2007 16 20 M Complete excision, no adjuvant Vimentin+, factor viii+,
CD31+, CD34+, cytokeratin+
Died at 6 months
of metastasis
Muzumder et al.
  (present case)
30 F Modified radical mastectomy,
postoperative radiotherapy 
(5000 cGy), thalidomide
Vimentin+, CD31+, CD34–,
h e r 2/neu (erbB-2)+, e r–,  
p r–, cytokeratin–
Alive at 9 months,
free of disease;  
on thalidomide
a  Excludes cases mentioned by Nascimento et al., 2008. 3
F = female; M = male; n r  = not reported; h e r 2/neu = human epidermal growth factor receptor; e r = estrogen receptor; p r = progesterone 
receptor.68
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Immunohistochemistry is an important adjunc-
tive procedure in the diagnosis of angiosarcoma—
particularly for poorly differentiated forms in which 
vascular channel formation is difficult to identify. 
Angiosarcomas express (to a greater or lesser de-
gree) the usual vascular antigens, including von 
Willebrand factor, CD31, and CD34. Although von 
Willebrand factor is the most specific of the vascular 
markers, it is also the least sensitive, often present 
in a few angiosarcomas as weak focal staining. On 
the other hand, CD31 combines both relative speci-
ficity with excellent sensitivity, and it is positive in 
approximately 90% of angiosarcomas of all types. 
Cytokeratin is present in about one third of soft-tissue 
angiosarcomas, particularly the epithelioid subtype, 
reflecting the fact that c k cannot be used as an absolute 
discriminant between angiosarcoma and carcinoma. 
Epithelioid angiosarcoma is a variant that is positive 
for CD31, but it is classically negative for CD34, 
which is another marker of endothelial differentia-
tion. In this case, the cells were negative for vimentin, 
e r, p r, and Bcl2. Many cases express c k  along with 
endothelial markers. The principal significance of 
those markers is the close resemblance they share 
with carcinoma. Immunohistochemical overexpres-
sion of h e r 2/neu in breast carcinomas is described 
as a predictor of response to alkylating agents or 
anthracycline therapies; however, its definite role in 
primary e a s  of breast remains to be explored 22. In 
our case, 2+ immunopositivity for h e r 2/neu was seen 
in tumour cells from both the tru-cut biopsy and the 
postoperative specimen.
An epithelioid morphology can also be found in 
other vascular tumours that vary considerably in their 
presentation and behaviour. Low-grade lesions such as 
epithelioid and spindle-cell hemangioendothelioma, 
and benign lesions such as epithelioid hemangioma, 
also appear in the differential diagnosis, as does a 
pleomorphic carcinoma 21. Epithelioid angiosarcoma 
is sometimes difficult to distinguish from epithelioid 
hemangioendothelioma. However, the presence of a 
solid growth pattern with necrosis and mitotic activity 
should generally be regarded as a diagnostic clue in 
favour of epithelioid angiosarcoma 22. The distinction 
from metastatic carcinoma, melanoma, and proximal-
type epithelioid sarcoma is based particularly on 
immunohistochemistry and a relative rarity of such 
lesions in this primary site. Epithelioid angiosarcoma 
may mimic the angiomatous variant of epithelioid 
sarcoma both in morphology and by the occasional 
expression of c k . However, angiosarcoma is more 
pleomorphic and usually expresses CD31 together 
with factor viii. Differentiating the epithelioid variant 
of angiosarcoma from the usual angiosarcoma de-
pends on typical cell morphology: nuclear indentation 
and immunonegativity for CD34 stain 22.
The recommended therapy for primary angiosar-
coma of the breast is simple mastectomy, because 
wide excision alone is associated with high local 
recurrence rates 23. Axillary lymph node dissection is 
not recommended, because the involvement of lymph 
nodes is extremely rare 23. According to the series 
reported by Nascimento et al., primary angiosarcoma 
of breast showed a high rate of metastasis and mor-
tality regardless of tumour grade 3. In that series, the 
authors reported no subset analysis with respect to 
the epithelioid variant of angiosarcoma, of which 5 
cases were seen. The most common sites of metastasis 
are lung, bone, liver, and skin. The roles of adjuvant 
radiotherapy and chemotherapy are not well defined 
in primary angiosarcoma of breast.
Primary e a s  of the breast, a rare variant of an-
giosarcoma, is a highly aggressive malignancy as-
sociated with poor survival. In the 4 reported cases, 
1 developed local recurrence, 1 developed axillary 
recurrence, and the remaining 2 developed distant 
metastasis. In our case, chest wall radiotherapy was 
given in view of the large size of the tumour and the 
intraoperative finding of deep fascia involvement. 
Adjuvant thalidomide 100 mg daily was started after 
surgery, because the benefits of other chemotherapy 
are doubtful, and a case of complete response to 
thalidomide in angiosarcoma of the breast has been 
reported from our institute 18.
4.  CONCLUSIONS
We report a rare and aggressive case of primary e a s  
of the breast—a disease that can be misdiagnosed as 
carcinoma because of similar histopathology. An immu-
nohistochemical panel including c k , vimentin, CD31, 
CD34, e r, p r, and h e r 2/neu should be used to differenti-
ate lesions with a similar histomorphology to reach a 
final diagnosis. Mastectomy with adjuvant radiotherapy 
and chemotherapy appears to be the best treatment 
modality. Thalidomide appears to be a promising drug 
in the management of angiosarcoma. Exploration of 
newer agents is warranted to improve survival.
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